Advancing the frontiers of biomedical research

The Institute for Research in Biomedicine (IRB Barcelona) is an independent, non-profit research center engaged in basic and applied biomedical science. The convergence of biology, chemistry, medicine, physics and computer science at IRB Barcelona provides a unique opportunity for the translation of basic biomedical research into innovation.

COLOSTAGE
NEW COMPANION DIAGNOSTIC TEST FOR COLORECTAL CANCER
COLOSTAGE
New companion diagnostic test for colorectal cancer

COMPANION DIAGNOSTIC TEST FOR DRUGS TARGETING TGF-BETA IN COLORECTAL CANCER

TECHNOLOGY
Novel therapies against TGF-beta for cancer treatment are emerging in the last years. Yet, in some patients, these treatments have shown lack of response. Our technology provides an accompanying diagnostic test, Colostage, to facilitate the selection of those patients who may benefit from treatment with novel drugs that target the TGF-beta signaling pathway. In addition, this test may be used to identify patients with poor prognosis.

IRB Barcelona researchers have demonstrated that CRC recurrence and metastasis depend strictly on TGF-beta signaling. They have also proven that treatment of mice with TGF-beta inhibitors drastically diminished the capacity of CRC cells to initiate metastasis in animal models and inhibited the expression of TGF-beta biomarkers in established CRC tumors in mice.

In CRC patient samples from a retrospective study we have demonstrated that Colostage biomarkers soundly correlate with the expression levels of TGF-beta. Therefore, patients with tumors exhibiting high levels of our biomarkers may benefit from adjuvant therapy with TGF-beta inhibitors.

CURRENT STAGE OF DEVELOPMENT
Our technology has been validated in a retrospective study with more than 1000 FFPE samples of colorectal cancer patients.

MORE INFORMATION

Dependency of Colorectal Cancer on a TGF-Beta-Driven Program in Stromal Cells for Metastasis Initiation.

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.

COMPETITIVE ADVANTAGE
• Innovative test to provide an integral solution for personalized medicine in colorectal cancer (CRC): to choose the right treatment for the right patient.
• The test identifies patients who will benefit from treatments targeting TGF-beta.
• Our Companion Dx test will help pharma companies developing TGF-beta targeted treatments to identify patients suitable for treatment.
• Our diagnostic device will help doctors to make informed and individualized treatment decisions, based on the patient’s risk to develop recurrent CRC and to respond to TGF-beta inhibitors.

PATENT STATUS

IRB RESEARCH TEAM
Prof. Eduard Batlle
Dr. Elena Sancho
COLORECTAL CANCER LABORATORY

CONTACT
Dr. Delia Zafra
Innovation Department - IRB Barcelona
+34 93 403 37 32
delia.zafra@irbbarcelona.org

IN COLLABORATION WITH